Falciparum Malaria prevents HIV-associated Cervical Cancer in East and Central Africa (Hypothesis)

Main Article Content

Michael Odida, Prof. Helga Rehder, Prof. Christoph Larsen Jürgen Freers, Prof. Rolf Schmauz, Priv.-Doz.Dr.med

Abstract

In many parts of the world the human immunodeficiency virus (HIV) and cervical cancer (CC) are associated, but four case-control studies from Mulago University Hospital, Kampala, a highly prevalent area of falciparum malaria  (FM), found no association. Adding to Kampala Tanzania and Rwanda with intermediate or low prevalence of FM and OR’s of 2.0 and 5.9, respectively, an inverse geographical distribution is noted. Similar to malariotherapy practised in Austria 120 years ago by injecting curable types of malaria HIV might be eliminated by more aggressive attacks of FM. Recently, experts proposed future research on HIV and cancer. Risks accounting for FM should be determined for HIV-associated CC.

Article Details

How to Cite
ODIDA, Michael et al. Falciparum Malaria prevents HIV-associated Cervical Cancer in East and Central Africa (Hypothesis). Medical Research Archives, [S.l.], v. 13, n. 5, may 2025. ISSN 2375-1924. Available at: <https://esmed.org/MRA/mra/article/view/6499>. Date accessed: 21 june 2025. doi: https://doi.org/10.18103/mra.v13i5.6499.
Section
Research Articles

References

1. Odida M, Löscher T, Rehder H, Schmauz R. Malaria and Cervical Cancer Risk from HPV in Kampala, Uganda. Epidemiol Public Health 2024; 2: 1040-3.
2. Stelzle D, Tanaka LF, Lee KK, et al. Estimates of the global burden of cervical cancer associated with HIV. Lancet Glob Health 2021; 9: e161–9.
3. Schmauz R, Okong P, De Villiers E ‐M., et al. Multiple infections in cases of cervical cancer from a high‐incidence area in tropical Africa. Int J Cancer 1989; 43:805–9.
4. Sekirime WK, Gray R. HIV Infection among Uganda Women with Cervical Cancer: a retrospective study. Gynecol Obstet Invest 2007; 63: 222–8.
5. Newton R, Ziegler J, Beral V, et al. A case-control study of human immunodeficiency virus infection and cancer in adults and children residing in Kampala, Uganda. Int J Cancer 2001; 92: 622–7.
6. Odida M, Sandin S, Mirembe F, Kleter B, Quint W, Weiderpass E. HPV types, HIV and invasive cervical carcinoma risk in Kampala, Uganda: a case-control study. Infect Agent Cancer 2011; 6: 8.
7. Odida M (personal communication, 2024).
8. Freitas DRC, Santos JB, Castro CN. Healing with malaria: a brief historical review of malariotherapy for neurosyphilis, mental disorders and other infectious diseases. Rev Soc Bras Med Trop 2014; 47: 260–1.
9. Mpunga T, Znaor A, Uwizeye FR, et al. A case–control study of HIV- infection and cancer in the era of antiretroviral therapy in Rwanda. Int J Cancer 2018; 143:1348–55.
10. Kahesa C, Mwaiselage J, Wabinga HR, Ngoma T, Kalyango JN, Karamagi CA. Association between invasive cancer of the cervix and HIV-1 infection in Tanzania: the need for dual screening. BMC Public Health 2008; 8: 262.
11. Rwanda Malaria Profile (Google, accessed July, 13th, 2024)
12. Tanzania Malaria Map (Google, accessed July, 13th, 2024)
13. Engels EA, Shiels MS, Barnabas RV, et al. State of the science and future directions for research on HIV and cancer: Summary of a joint workshop sponsored by IARC and NCI. Int J Cancer 2024; 154: 596–606.
14. Sitas F, Parkin DM, Chirenje M, Stein L, Abratt R, Wabinga H. Part II: Cancer in Indigenous Africans—causes and control. Lancet Oncol 2008; 9: 786–95.
15. Schmauz R, Mugerwa JW, Wright DH. The distribution of non‐Burkitt, non‐Hodgkin’s lymphomas in Uganda in relation to malarial endemicity. Int J Cancer 1990; 45: 650–3.
16. Cook-Mozzafari P, Newton R, Beral V, Burkitt DP. The geographicl distribution of Kaposi’s sarcoma and lymphomas in Africa before the AIDS epidemic. Br J Cancer 1998; 78(11): 1521-1528.
17. Odida M, Schmauz R, Lwanga SK. Grade of malignancy of cervical cancer in regions of Uganda with varying malarial endemicity. Int J Cancer 2002; 99: 737–41.
18. Carpenter LM, Newton R, Casabonne D, Ziegler J, Mbulaiteye S, Mbiddde E, Wabinga H, Jaffe H, Beral V. Antibodies against malaria and Epstein-Barr virus in childhood Burkitt-lymphoma: A case-control study in Uganda. Int J Cancer 2008;122, 1319-1322.
19. Abou Chacra I., FenollarF., Diop K. What Do We Currently Know? Front Cell Infect.Microbiol. 2022 Jan 18;1:672429
20. Datoo MS, Dicko A, Tinto H, et al. Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentric, double-blind, randomised, phase 3 trial. Lancet 2024; 403: 533-544.